Alector Follows Cassava With An Alzheimer’s Miss

AL002 failed across the board in a mid-stage study, and Alector has trimmed its workforce as it refocuses on its other two assets.

Tumbling blocks
AL002 Fails To Stand Up In Alzheimer's Studies • Source: Shutterstock

More from Clinical Trials

More from Therapy Areas